Journal
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
Volume 310, Issue 4, Pages H455-H465Publisher
AMER PHYSIOLOGICAL SOC
DOI: 10.1152/ajpheart.00726.2015
Keywords
stem cell therapy; pluripotent stem cell; angiogenesis; myocardial infarction; peripheral arterial disease; hindlimb ischemia
Funding
- National Institutes of Health [HL098688, EB020235, HL089315, HL088957]
- Department of Veterans Affairs Biomedical Laboratory Research and Development Merit Review Award [1I01BX002310]
- Stanford Chemistry Engineering AMP
- Medicine for Human Health
- Stanford Cardiovascular Institute
- McCormick Gabilan fellowship
Ask authors/readers for more resources
Stem cell therapy is a promising approach for the treatment of tissue ischemia associated with myocardial infarction and peripheral arterial disease. Stem and progenitor cells derived from bone marrow or from pluripotent stem cells have shown therapeutic benefit in boosting angiogenesis as well as restoring tissue function. Notably, adult stem and progenitor cells including mononuclear cells, endothelial progenitor cells, and mesenchymal stem cells have progressed into clinical trials and have shown positive benefits. In this review, we overview the major classes of stem and progenitor cells, including pluripotent stem cells, and summarize the state of the art in applying these cell types for treating myocardial infarction and peripheral arterial disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available